OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Danielle Hammond, Sanam Loghavi, Sa A. Wang, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Danielle Hammond, Sanam Loghavi, Sa A. Wang, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Showing 9 citing articles:
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Wei‐Ying Jen, Hagop M. Kantarjian, Tapan M. Kadia, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 30-47
Open Access | Times Cited: 18
Wei‐Ying Jen, Hagop M. Kantarjian, Tapan M. Kadia, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 30-47
Open Access | Times Cited: 18
Advancements and Challenges in the Treatment of AML
Yasmin Abaza, Christine M. McMahon, Jacqueline S. Garcia
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
Yasmin Abaza, Christine M. McMahon, Jacqueline S. Garcia
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
Venetoclax Resistance in Acute Myeloid Leukemia
Sylvain Garciaz, Marie‐Anne Hospital, Yves Collette, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1091-1091
Open Access | Times Cited: 10
Sylvain Garciaz, Marie‐Anne Hospital, Yves Collette, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1091-1091
Open Access | Times Cited: 10
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
Firas El Chaer, Anthony J. Perissinotti, Sanam Loghavi, et al.
Leukemia (2024)
Closed Access | Times Cited: 3
Firas El Chaer, Anthony J. Perissinotti, Sanam Loghavi, et al.
Leukemia (2024)
Closed Access | Times Cited: 3
The Validation of Digital PCR-Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients with Acute Myeloid Leukemia
Jing Di, Tao Sheng, Rajeev Aurora, et al.
Journal of Molecular Diagnostics (2024)
Closed Access | Times Cited: 1
Jing Di, Tao Sheng, Rajeev Aurora, et al.
Journal of Molecular Diagnostics (2024)
Closed Access | Times Cited: 1
HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML
Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-9
Closed Access
Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-9
Closed Access
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
Shan Zheng, Yuxin Tong, Linlin Yang, et al.
Annals of Hematology (2024)
Closed Access
Shan Zheng, Yuxin Tong, Linlin Yang, et al.
Annals of Hematology (2024)
Closed Access
Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML
Yitian Wu, Shuai Zhang, Ru Feng, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Yitian Wu, Shuai Zhang, Ru Feng, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Mutation- and MRD-informed treatments for transplant-ineligible patients
Curtis A. Lachowiez, Courtney D. DiNardo
Hematology (2024) Vol. 2024, Iss. 1, pp. 168-177
Closed Access
Curtis A. Lachowiez, Courtney D. DiNardo
Hematology (2024) Vol. 2024, Iss. 1, pp. 168-177
Closed Access
